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Key Clinical Message
Septo-optic dysplasia (SOD) is a rare condition for which the precise etiology
is still unclear. Elucidating the genetic component of SOD is a difficult but nec-
essary task for the future. We describe herein a novel HESX1 c.475C>T
(p.R159W) mutation and demonstrate its potential pathogenicity in the devel-
opment of this rare disease.
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Introduction
Septo-optic dysplasia (SOD) is a congenital developmental
anomaly of the brain, possibly a monotopic field defect,
resulting in the combination of the absence of septum pellu-
cidum (the “septo” component), optic nerve hypoplasia (the
“optic” component), and hypopituitarism [1, 2]. It affects
one in 10,000 livebirths with a 1:1 ratio between females and
males [3]. This condition was first reported in 1941 by Reeves
who described a patient with a combination of absence of the
septum pellucidum and hypoplasia of the optic nerve [4]. In
subsequent years, more cases with the same defects were
described, and in 1956, De Morsier termed this condition
“septo-optic dysplasia” [5]. The pituitary component of this
condition was later identified in 1970, when Hoyt et al.
described clinical evidence of hypopituitarism in four chil-
dren with radiological evidence of SOD [6]. The spectrum of
clinical manifestations in SOD is quite broad, but the three
classical features are (1) abnormalities of midline structures
(e.g., corpus callosum, septum pellucidum, and anterior
commissure), (2) congenital hypothalamic-pituitary insuffi-
ciency, and (3) optic nerve hypoplasia [1].
Septo-optic dysplasia is considered a highly heteroge-
neous condition in which the precise etiology is still
unclear and believed to be multifactorial with both envi-
ronmental and genetic components [7]. To date, a num-
ber of mutations in critical developmental genes that
control brain morphogenesis have been identified as pos-
sible genetic causes of SOD [8]. This includes the home-
obox-containing transcriptional repressor HESX1, an
essential regulator of forebrain and pituitary development
in mice [9–11] and humans [12, 13].
HESX1 maps to chromosome 3p14.3 (human genome
build: GRCh38), and its open reading frame (ORF) is highly
conserved among different vertebrates [14]. HESX1 proteins
contain a homeodomain that is responsible for DNA bind-
ing, and two repressor domains, one in the N-terminal (eh1
and HRPW motifs) and one in the C-terminal home-
odomain [15]. Although direct transcriptional targets for
HESX1 remain unknown, HESX1 binds to an artificial
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consensus sequence (50-TAATYNRATTA-30) called P3 [16],
and repression is facilitated by the interaction of HESX1 with
several corepressors (e.g., TLE/groucho) [15, 17, 18]. Mice
carrying Hesx1 null or specific point mutations identified in
SOD patients show forebrain and pituitary phenotypes that
closely resemble human SOD, suggesting a conserved func-
tion for HESX1 in mammals [9, 19]. Here, we report the
identification of a novel HESX1 p.R159W mutation in a case
of SOD, which broadens our understanding of the genetic
causes of this important and complex human condition.
Subjects and Methods
Study subject
The proband, a male infant (II-1; Fig. 1A), was born at
37 weeks’ gestation with a birth weight of 2.126 kg to a
healthy 27-year-old mother. At 3 months of age, his
length was 46.4 cm and his head circumference 34 cm,
with a body weight of 3.74 kg. He had been diagnosed
prenatally with gastroschisis and underwent multiple
surgeries in the first 2 months of life to repair the gas-
troschisis and to manage the ensuing complications,
including abdominal compartment syndrome and wound
dehiscence. During that period and beyond, he also suf-
fered from multiple urinary tract, respiratory tract, and
central line infections; septic shock, conjugated and
unconjugated hyperbilirubinemia, anemia, and thrombo-
cytopenia. At about 4 months of life, the glucose infusion
rate (GIR) in his total parenteral nutrition was about
14–15 mg/kg/min, but as his GIR was being weaned, he
developed hypoglycemia with his blood glucose dropping
to about 1.3 mmol/L. He had a normal response to the
low-dose ACTH (cosyntropin) stimulation test and did
not have any biochemical evidence of adrenocortical
insufficiency, although he responded well to short courses
of stress-dose corticosteroids intermittently. He was also
noted to have growth hormone deficiency, for which
replacement therapy or stimulation test was not consid-
ered given the acute illness of the proband, who never
managed to leave the intensive care unit. The proband
showed low free thyroxine (T4) and triiodothyronine
(T3) levels, but normal thyroid-stimulating hormone
(TSH). There is no clinical evidence of hypogonadism.
Moreover, he was noted to have circular pendular nystag-
mus. Electroencephalography (EEG) showed diffuse
Figure 1. Identification of a HESX1 c.475C>T (p.R159W) mutation in a patient with septo-optic dysplasia. (A) The proband (arrow) and his
mother were found to be heterozygous for c.475C>T. The father and the female sibling could not be screened. (B) MRI sagittal view of the
proband brain. Note the thin corpus callosum (*) and the ectopic posterior pituitary (arrow), indicative of a failure to descend. (C)
Electropherogram showing the heterozygous variant. Note the presence of the C>T mutation in the patient compared to a healthy control
individual. (D) Schematic representation of HESX1 functional domains. The eh1 and the HPRW domains at the N-terminus are responsible for the
interaction of HESX1 with corepressors of the TLE/Groucho family. The homeodomain at the C-terminus mediates DNA binding and interaction
with nuclear corepressor. The position of the p.R159W substitution is indicated. (E) Protein homology analysis of the third helix of the
homeodomain region containing the R159W substitution. R159 has been conserved during evolution from flies to humans.
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slowing suggestive of encephalopathy, but there were no
epileptiform discharges nor was there any correlation with
the abnormal eye movements.
Ophthalmologic evaluation at almost 5 months of age
revealed bilateral optic nerve hypoplasia. Brain MRI per-
formed shortly thereafter confirmed that the optic nerves
and chiasm were hypoplastic; in addition, the left olfac-
tory nerves, bulb, and tract were not visible, and the pitu-
itary gland was extremely hypoplastic with an ectopic
posterior pituitary bright spot. The septum pellucidum
was present, but the corpus callosum was very thin
(Fig. 1B). Nonetheless, the constellation of optic nerve
hypoplasia and hypoplastic pituitary gland was highly
suggestive of SOD, so Sanger sequencing of all the coding
exons and the exon/intron boundaries of HESX1 was per-
formed.
Mutation detection
DNA isolated from the proband was polymerase chain
reaction (PCR)-amplified and sequenced in order to iden-
tify potential mutations in the HESX1 coding exons and
flanking introns. Sanger sequencing revealed a heterozy-
gous probably pathogenic variant: c.475C>T (p.R159W)
[NCBI Reference Sequence: NM_003865.2] (Fig. 1C). The
resulting mutant p.R159W protein was functionally
assessed to verify its pathogenicity.
In vitro mutagenesis
The following PCR primer sets were designed to introduce
the c.475 C>T mutation into the wild-type HESX1 cDNA
via PCR site-directed mutagenesis: 5-ATGTCTCCCA
GCCTTCAGGA-30 and 50-CAGTTTTGCACGCCAATTTT
GAAACCA-30; 50-AATTGGCGTGCAAAACTGAAAAG-30
and 50-TATTCCAGCAGATTTGTGTTG-30. The full-length
HESX1 cDNA containing the mutation was then cloned
into the pM vector (Clontech) in frame with the Gal4
DNA-binding domain (Gal4BD) using EcoRI and SalI
restriction enzymes. The product of this expression vector
is a fusion protein of the N-terminal region of Gal4 (1–147
amino acids) and either the WT or mutant HESX1. For
localization experiments, the full-length HESX1 cDNA con-
taining the mutation was cloned into the HA-pcDNA3.1
vector (Invitrogen) in frame with the HA tag using EcoRI
and XhoI restriction enzymes.
Cell culture and transfection
Human embryonic kidney (HEK)-293T and CHO (Chi-
nese hamster ovary) cells were maintained in DMEM sup-
plemented with 10% fetal bovine serum, 50 U/mL
penicillin, and 50 lg/mL streptomycin. For functional
assays, cells were transfected with DNA using Lipofec-
tamine 2000 (Life Technologies) according to the manu-
facturer’s protocol.
Visualization of subcellular localization
HEK-293T cells were cultured on gelatine-coated coverslips
and transfected with HA-HESX1-WT and HA-HESX1
p.R159W expression constructs. 24 h post-transfection,
cells were fixed in 4% PFA and immunofluorescence was
performed. Rabbit anti-HA (Sigma) and goat anti-rabbit
568 (Alexa Fluor, Thermo Fischer) antibodies were used,
respectively, for primary and secondary incubation. Imag-
ing was performed using a Zeiss Axioplan fluorescence
microscope.
Western blots and immunoprecipitation
HEK-293T cells were transfected with either HA-HESX1-
WT or HA-HESX1-R159W constructs and harvested 48 h
after transfection. Whole-cell lysates were extracted using
basic cell lysis solution (50 mM Tris-Base pH 7.6,
150 mM NaCl, 1% Triton X-100) supplemented with a
Protease Inhibitor Cocktail (Roche). 10 lg of WT and
mutant proteins was separated by SDS-PAGE (12.5%
polyacrylamide), and membranes were incubated with
a high-affinity anti-HA-peroxidase rat antibody (Roche)
overnight at 4°C. A mouse anti-glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) antibody from Millipore
was used to assess total loaded protein. Immunoreactive
proteins were visualized using the Pierce ECL2 Western
Blotting Substrate (Thermo Scientific) according to the
manufacturer’s instructions. The density of protein bands
was quantified using the ImageJ software. For immunopre-
cipitation, approximately 0.5 mg of total protein from
HEK-293T cells transfected with either Gal4-HESX1-WT
or Gal4-HESX1-R159W constructs was incubated with
anti-Gal4BD (binding domain) bound to protein G–
Sepharose beads at 4°C overnight. Immunoprecipitates
were then subjected to Western blot using an anti-HESX1
antibody. 25 lg (5%) of total protein extract was used as
INPUT.
qRT-PCR
Total RNA from HEK-293T cells transfected with either
HESX1-WT or HESX1-R159W expression constructs was
isolated using the RNeasy micro kit (QIAGEN) with DNa-
seI treatment. First-strand cDNA was synthetized with
iScript Reverse Transcriptase (BIO-RAD).
Real-time PCR was performed with iTaq Universal SYBR
Green (BIO-RAD). Gene expression was determined
relative to GAPDH via the DCt method. Primers used
ª 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. 465
S. Pozzi et al. Hesx1 in SOD
are here listed. Hesx1-FW: 50-GATCTTCCCAGTGAGA
CTTC-30; Hesx1-REV: 50-CAGGGTAGCAGTTCACTCT
A-30; GaPDH-FW: 50-ATGACATCAAGAAGGTGGTG-30;
GaPDH-REV: 50-CATACCAGGAAATGAGCTTG-30.
Luciferase assays
For dual luciferase assay experiments, approximately
50,000 CHO cells per well were seeded into each well of a
tissue culture 24-well plate. Transfection was performed
24 h after seeding, whereas harvesting for analysis
occurred 48 h after transfection. To assess the ability of
WT and R159W mutant HESX1 proteins to directly bind
DNA and repress transcription, a luciferase reporter plas-
mid containing a SV40 promoter and six copies of the
DNA-binding motif P3 was used, given the high DNA-
binding affinity of HESX1 for P3 [11, 16, 20]. CHO cells
were cotransfected with 80 ng of Renilla control vector,
100 ng of the 6P3-SV40 luciferase reporter, and 100 ng of
WT and mutant HESX1 expression vectors. To evaluate
the ability of WT and R159W HESX1 to repress tran-
scription independently from their DNA-binding activity,
we used a luciferase reporter plasmid containing Gal4-
binding sites (Gal4BS-SV40 luciferase reporter) [11].
CHO cells were cotransfected with 80 ng of Renilla con-
trol vector, 100 ng of Gal4BS-SV40 luciferase reporter,
and 100 ng of Gal4-HESX1 expression vectors. In these
fusion proteins, the Gal4-binding domain allows for
strong binding, but it is incapable of conferring transcrip-
tional ability unless fused to a protein that can contribute
to transcriptional function [21]; therefore, WT and
R159W HESX1 proteins could be evaluated for their abil-
ity to repress transcription independently by their direct
binding to DNA. The total amount of transfected DNA
was normalized to 350 ng per well by the addition of an
empty vector (pBlueScript, Stratagene). Cells were har-
vested and assayed for luciferase activity using the Dual
luciferase Reporter Assay System (Promega). Lumines-
cence was measured using a BMG FLUOstar Optima
multiplate reader (BMG Labtech Gmbh). Experiments
were performed in triplicate and repeated at least three
times.
Results
Mutation analysis
The R(Arg)159 residue is located in the HESX1 DNA-
binding domain and is highly conserved in vertebrates
from fish to humans (Fig. 1D and E). This variant has
not been reported in a homozygous state in any of 60,277
individuals in the Exome Aggregation Consortium
(ExAC) database [22], which contains sequencing data on
individuals without “severe pediatric disease,” but it
was found in a heterozygous state in two of 33,194
(~0.06%) non-Finnish Europeans and 60,277 individuals
(1.659 9 105) in this database. It was predicted by Poly-
Phen-2 [23] to be “probably damaging” and by SIFT [24]
(Sorting Intolerant from Tolerant) to be “deleterious”.
The proband’s parents were tested for this specific
HESX1 variant, and his mother was found to carry the
same heterozygous variant. The mother herself was born
with a birth weight of 2.977 kg, had had one prior nor-
mal pregnancy, a minor surgical procedure, and was
otherwise healthy. Her height was on the 10th percentile,
which was entirely consistent with her expected height
based on her parental heights. She had normal optic
nerves and underwent a comprehensive evaluation by an
endocrinologist that was unremarkable with normal
adrenocorticoid, growth hormone, thyrotrope, and gona-
dotrope axes. She therefore had no clinical nor hormonal
evidence of hypopituitarism or optic nerve hypoplasia,
but she had never had a brain MRI.
Functional studies
First, we investigated the cellular localization of the
HESX1 p.R159W mutant protein in comparison with
HESX1-WT. Indirect immunofluorescence on transfected
HEK-293T cells revealed weaker nuclear staining in cells
transfected with a construct expressing the mutant HA-
HESX1-R159W compared with those transfected with a
plasmid expressing the HA-HESX1-WT protein, in addi-
tion to sporadic cytoplasmic-only accumulation (Fig. 2A,
A0-C0; Fig. 2A, B0-D0, arrows). This observation was con-
firmed by Western blot analysis from transfected cells,
which showed an approximate 60% reduction in levels of
expression of HESX1-R159W mutant protein compared
with HESX1-WT (Fig. 2B). This reduction was not a
transfection artifact because mRNA levels encoding WT
and mutant HESX1 were similar in transfected cells as
analyzed by qRT-PCR (Fig. 2C). These experiments sug-
gest that the R159W substitution leads to the generation
of a mutant protein with reduced nuclear localization in
transfected cells, suggesting a defect in protein synthesis,
degradation, or both.
Next, we sought to assess the transcriptional repressing
activities of the HESX1-R159W mutant protein in com-
parison with HESX1-WT. CHO cells were transfected
with constructs expressing Gal4 fusion proteins (WT and
HESX1-R159W) and a luciferase reporter containing
Gal4-binding sites (Gal4BS-SV40). In this experimental
context, the reporter activity is only dependent on the
Gal4 DNA-binding domain, which when activated allows
for stabilization of protein expression, ensuring long half-
lives of the fusion protein’s product [25] (Fig. 3A).
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Indeed, stabilization of the HESX1-R159W protein by
fusion to the Gal4-binding domain (BD) was demon-
strated by immunoprecipitation (IP) with an anti-Gal4-
BD antibody of protein extracts from HEK-293T cells
transfected with the WT or (p.R159W) mutant Gal4-
HESX1 constructs, followed by detection of the immuno-
precipitated proteins by Western blot using an antibody
against HESX1. As shown in Figure 3E, both HESX1
fusion proteins (Gal4-WT and Gal4-R159W) could be
detected (41-kDa band corresponding to the fusion pro-
duct). No band was obtained in the control lane, repre-
sented by nontransfected (NT) HEK-293T cells.
Having shown that protein levels are similar, we
assessed the repressing activities of the fusion proteins.
Cells transfected with constructs expressing either Gal4-
HESX1-WT or Gal4-HESX1-R159W proteins showed the
same levels of repression of reporter activity
(0.45  0.004 and 0.43  0.003, respectively) (Fig. 3B).
These results suggest that the repressing activities of WT-
HESX1 and HESX1 (p.R159W) mutant proteins are com-
parable in this Gal4 system.
Next, we decided to evaluate the ability of the HESX1-
R159W mutant protein to bind DNA. We have developed
a method to analyze the HESX1 DNA binding activities
without the need to perform EMSA, a more hazardous
method involving the use of radioisotopes [20]. CHO
cells were cotransfected with the 6P3-luciferase reporter,
and constructs expressing either Gal4-HESX1-WT or
Gal4-HESX1-R159W proteins. Therefore, in this set of
experiments, the reporter activity depends on the direct
binding of HESX1 to the P3-binding sites and is indepen-
dent from Gal4 (Fig. 3C). Cells expressing Gal4-HESX1-
WT showed a 33% reduction (0.67  0.006) in the levels
of SV40-mediated transcriptional activation when com-
pared to cells transfected with only the 6P3 reporter vec-
tor (i.e., considered as basal level of luciferase activity)
(Fig. 3D). In contrast, cells expressing Gal4-HESX1
(p.R159W) mutant protein failed to repress the basal
reporter activation and, indeed, showed higher levels
(153%) of luciferase activity (1.53  0.013) (Fig. 3D),
possibly due to sequestration of corepressors from the
SV40 promoter (see Discussion section). These results
suggest that the failure of the HESX1 (p.R159W) mutant
protein to repress the transcriptional activation of the P3-
SV40 luciferase reporter is caused by impairment of its
DNA binding properties.
(A)
A′ B′
C′ D′
(B)
(C)
Figure 2. Subcellular localization and Western blot analysis of wild-type (WT-HESX1) and HESX1-R159W proteins. (A) Indirect
immunofluorescence on HEK-293T cells transfected with constructs expressing either HA (human influenza hemagglutinin)-tagged HESX1-WT
(A0-C0) or the HESX1-R159W proteins (C0-D0). Nuclei are counterstained with DAPI. Both the wild-type and the mutant proteins localized to the
nuclei of transfected cells (red). However, weaker nuclear staining can be observed in cells transfected with the construct expressing HA-HESX1-
R159W, in combination with infrequent cytoplasmic-only accumulating cells (B0-D0, arrows). Scale bar = 50 lm (A0-B0), 100 lm (C0-D0).
(B) Western blot of total protein extracts from HEK-293T cells transfected with constructs expressing wild-type (L1) or mutant (L2) R159W HA-
HESX1 proteins. Note the reduced levels of expression of R159W compared with wild-type HESX1. L3 represents nontransfected HEK-293T cells.
The expected size of HA-HESX1 and HA-HESX1-R159W proteins is 25 kDa. GAPDH (38 kDa) was used as loading control. (C) qRT-PCR showing
levels of Hesx1 expression relative to Gapdh in HEK-293T cells transfected with equal amount of HESX1-WT and HESX1-R159W expression
vectors. Error bars represent mean  SEM. The difference between the two samples is not statistically significant.
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Discussion
In this study, we have identified a novel HESX1 mutation
in a patient with SOD and demonstrated that the result-
ing mutant protein is functionally compromised.
Firstly, we show that HESX1 (p.R159W) mutant pro-
tein localizes to the nucleus, although accumulation of
this mutant protein is compromised, as shown by
immunostaining and Western blot analyses. It is well
known that point mutations in conserved residues can
cause protein misfolding, which results in the activation
of degradation pathways [26]. R159 is a highly conserved
residue within the homeodomain from Drosophila to
humans, and it is present in 347 of 350 homeodomain-
containing proteins [27]. It is likely that the R159W sub-
stitution leads to compromised protein structure and
reduced stability of the mutant protein. However, this is
corrected when the mutant protein is fused to the Gal4-
DNA-binding domain, as this peptide confers greater sta-
bility [25].
Secondly, we demonstrate that the R159W substitution
does not affect repression because both Gal4-HESX1-WT
and Gal4-HESX1-R159W repressing activities are compa-
rable on a luciferase reporter containing Gal4-binding
Figure 3. Functional in vitro luciferase assays of wild-type and
R159W-HESX1 proteins. The luciferase activity of HEK-293T cells
cotransfected with Renilla and either the Gal4BS-SV40 (B) or the 6P3-
SV40 (D) reporter represent the basal level of transcriptional activation
in this system and have been used to normalize the subsequent data.
Bars represent mean  1 SD, P< 0.001 (**), t-test. (A) Schematic
representation of the mammalian one-hybrid system using the Gal4-
SV40-luciferase reporter. In the absence of HESX1, the reporter is
constitutively active due to the presence of the SV40 promoter. When
the GAL4-BD (binding domain moiety) fusion protein binds to the
Gal4-binding site upstream the SV40 promoter, HESX1 is able to
repress the reporter activity, modulating the luciferase response. In
this context, the repressor activity of WT and R159W-HESX1 can be
evaluated independently by their ability to bind DNA. (B) Transfection
of constructs expressing either Gal4-WT and Gal4-R159W-HESX1
proteins results in a 55–57% reduction in luciferase activity. (C)
Schematic representation of the mammalian one-hybrid system using
the P3-SV40-luciferase reporter. In the absence of HESX1 proteins,
the luciferase reporter is constitutively active due to the presence of
the SV40 promoter. In the presence of the transcriptional repressor
HESX1, the direct binding to the P3 consensus site causes a reduction
in the basal levels of luciferase transcriptional activity. (D) Transfection
with Gal4-WT HESX1 expression constructs leads to a 33% reduction
in the basal levels of luciferase activity, whereas the mutant construct
(R159W) causes a 53% activation. (E) Immunoprecipitation of HESX1
(WT and R159W) proteins fused to the Gal4-binding domain in HEK-
293T cells. Cells were transfected with plasmids expressing Gal4-
HESX1-WT or Gal4-HESX1-R159W and immunoprecipitated with an
anti-Gal4-BD antibody. Immunoprecipitates were blotted and detected
with an anti-HESX1 antibody. Specific immunoreactive bands are
indicated with arrows. The 41-kDa band corresponds to the HESX1
protein (WT or R159W, 22 kDa) fused to the Gal4-binding domain
(19 kDa). NT corresponds to nontransfected HEK-293T cells. 5% of
the total protein extract for each sample was not immunoprecipitated
and used as INPUT. Given the low efficiency of the anti-HESX1
antibody in Western blot alone, together with the low levels of
HESX1 protein expression, no Gal4-HESX1 band (WT or R159W) could
be detected in the INPUT. Star(*) marks nonspecific bands, possibly
corresponding to the immunoglobulins light chain.
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sites (Fig. 3B), therefore independently on direct HESX1
or HESX1 (pR159W) binding. This finding is not unex-
pected, as the eh1 motif at the N-terminus of HESX1
p.R159W, which is necessary for interactions with TLE/
Grouch corepressors [15, 17], is not affected in the
mutant protein.
In contrast, when the repressing activity of the Gal4-
HESX1-WT or Gal4-HESX1-R159W fusion proteins was
assessed in a system dependent on direct binding of the
HESX1-WT or HESX1-R159W to the P3 consensus DNA,
the mutant protein showed impaired repression relative
to the wild type (Fig. 3D). This suggests that the mutant
protein has defective DNA binding properties compared
with HESX1-WT. In fact, the R159W substitution falls
within the highly conserved homeodomain, which is
essential for the recognition of core-binding sites (re-
viewed by Gehring [28]). Moreover, SIFT in silico analy-
sis predicts that the R159W substitution is deleterious
and could affect protein function [24].
Taken together, our data support previous mouse work
showing that point mutations in the HESX1 home-
odomain result in loss of DNA binding and protein func-
tion [9, 19], suggesting a pathogenic role for the R159W
mutation in our patient with SOD. However, the fact that
the mother of the affected patient is asymptomatic despite
carrying the heterozygous p.R159W suggests that there is
variable penetrance of this mutation and other unidenti-
fied alleles may also contribute to the observed pheno-
type. In fact, a multitude of single nucleotide
substitutions in different developmental genes have been
reported to be associated with SOD [9, 29–31]. Under-
standing the role of oligogenicity in the generation of
SOD and other human phenotypes is a difficult but nec-
essary task for the future. In conclusion, we have identi-
fied a novel and pathogenic, most likely by oligogenic
interaction, HESX1 (p.R159W) substitution in association
with SOD.
Since the submission of this manuscript, the proband’s
sisters (one born after his passing), aged 3 and 10½ years,
have been found to carry the same HESX1 variant. Like
their mother, both of them are completely asymptomatic
with normal height, normal vision, and normal neurode-
velopment, further underscoring the variable penetrance
of this variant.
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